TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
To find out if it is the right fit for your goals, start with a complimentary consultation at our West Nashville center
Although GHK-Cu and Pal-GHK are widely used in anti-wrinkle products available on the cosmetic market, the published information on their skin permeability, effectiveness, physicochemical properties and so on is insufficient
Higuchi M et al
That being said, the research team of McCoy et al examined the potential of the nootropic compound to induce spinogenesis and synaptogenesis
